NCT01862926View on ClinicalTrials.gov

Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Interstitial Lung DiseaseSclerodermaIdiopathic Inflammatory MyositisMixed Connective Tissue Disease
Interventions
DRUG

Rituximab

DRUG

Cyclophosphamide

Trial Locations (1)

SW3 6NP

Royal Brompton Hospital, London

All Listed Sponsors
collaborator

Imperial College London

OTHER

collaborator

University of East Anglia

OTHER

collaborator

University College London Hospitals

OTHER

lead

Royal Brompton & Harefield NHS Foundation Trust

OTHER

NCT01862926 - Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD | Biotech Hunter | Biotech Hunter